---
layout: default
title: Fluocinolone Acetonide
parent: Model Prediction Only (L5)
nav_order: 391
evidence_level: L5
indication_count: 4
---

# Fluocinolone Acetonide
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **4** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Fluocinolone Acetonide: From Topical Corticosteroid Therapy to Hypertrophic Lichen Planus

## One-Sentence Summary

Fluocinolone acetonide is a potent topical glucocorticoid with anti-inflammatory and immunosuppressive activity.
The TxGNN model predicts it may be effective for **hypertrophic lichen planus**, but **no clinical trials and no publications** currently support this prediction, so it remains a computational hypothesis only.

---

## Quick Overview

| Item | Content |
|------|------|
| Predicted New Indication | Hypertrophic lichen planus |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 3 |
| Recommended Decision | Hold |

Three other lichen planus variants were also predicted. All are L5 with no supporting trials or literature.

| Rank | Predicted Indication | TxGNN Score |
|------|------|------|
| 1 | Hypertrophic lichen planus | 99.42% |
| 2 | Lichen planus pigmentosus | 99.42% |
| 3 | Annular atrophic lichen planus | 99.42% |
| 4 | Lichen planus pemphigoides | 99.34% |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, fluocinolone acetonide is a potent topical glucocorticoid. Glucocorticoids are broadly anti-inflammatory and immunosuppressive, and mechanistically this may be applicable to lichen planus.

Hypertrophic lichen planus is a T-cell-mediated inflammatory skin disease. A glucocorticoid-responsive mechanism is therefore plausible. This is class-level plausibility only. There is no drug-specific clinical evidence, and the high TxGNN score is a computational prediction, not clinical support.

The other three predictions likely come from the shared lichen planus neighborhood in the knowledge graph. Each has its own caveats:
- **Lichen planus pigmentosus:** nothing in the data shows whether topical corticosteroids work in this pigmentary variant.
- **Annular atrophic lichen planus:** this is a rare variant, and potent steroids carry a risk of skin atrophy.
- **Lichen planus pemphigoides:** it involves autoimmune blistering, which topical fluocinolone acetonide alone may not address.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 2300559 | DERMOTIC OIL EAR DROPS |
| 873292 | DERMA SMOOTHE/FS LIQ 0.01% |
| 2459655 | OTIXAL |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests only on a model score and class-level mechanistic plausibility. There are no trials or publications, and safety data are incomplete. Evidence is not yet sufficient to advance beyond a research question.

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications
- Mechanism of action data (for example, from DrugBank)
- A targeted search for clinical and literature evidence of topical corticosteroids in each lichen planus variant
- Confirmation that the marketed formulations (currently ear drops and a topical liquid) match the route needed for skin lesions
- Approved indication text for the Canadian products, to establish the original indication
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

